The increasing indications for allogeneic stem-cell transplant in patients with hematologic malignancies and non-malignant diseases combined with improved clinical outcomes have contributed to increase the number of long-term survivors. However, survivors are at increased risk of developing a unique set of complications and late effects, besides graft-versus-host disease and disease relapse. In this setting, the management capacity of a single health-care provider can easily be overwhelmed. Thus, to provide appropriate survivorship care, a multidisciplinary approach for the long-term follow-up is essential. This review aims at summarizing the most relevant information that a health-care provider should know to establish a follow-up care plan, in the light of individual exposures and risk factors, that includes all organ systems and considers the psychological burden of these patients.

Optimal delivery of follow-up care after allogeneic hematopoietic stem-cell transplant: Improving patient outcomes with a multidisciplinary approach

Giaccone L.
First
;
Felicetti F.;Butera S.;Faraci D.;Cerrano M.;Brunello L.;Bruno B.
Co-last
2020-01-01

Abstract

The increasing indications for allogeneic stem-cell transplant in patients with hematologic malignancies and non-malignant diseases combined with improved clinical outcomes have contributed to increase the number of long-term survivors. However, survivors are at increased risk of developing a unique set of complications and late effects, besides graft-versus-host disease and disease relapse. In this setting, the management capacity of a single health-care provider can easily be overwhelmed. Thus, to provide appropriate survivorship care, a multidisciplinary approach for the long-term follow-up is essential. This review aims at summarizing the most relevant information that a health-care provider should know to establish a follow-up care plan, in the light of individual exposures and risk factors, that includes all organ systems and considers the psychological burden of these patients.
2020
11
141
162
Allografting; Complications; Long-term
Giaccone L.; Felicetti F.; Butera S.; Faraci D.; Cerrano M.; Dionisi Vici M.; Brunello L.; Fortunati N.; Brignardello E.; Bruno B.
File in questo prodotto:
File Dimensione Formato  
jbm-11-141.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 3.7 MB
Formato Adobe PDF
3.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1771693
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact